Literature DB >> 10926443

Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of Escherichia coli to fluoroquinolones in urology.

F Wagenlehner1, J Stöwer-Hoffmann, W Schneider-Brachert, K G Naber, N Lehn.   

Abstract

During the years 1991-1996 an increase in fluoroquinolone-resistant Escherichia coli was observed at the Urological Department of the Municipal Hospital in Straubing, Germany. A prospective study was undertaken to investigate the influence of single-dose prophylaxis (SDP) using 500 mg ciprofloxacin orally on the level of resistance to ciprofloxacin of faecal E. coli. One hundred and five patients were recruited to the study: E. coli resistance to ciprofloxacin before prophylaxis was 3% (3/91) in contrast to 12% (5/42) after prophylaxis (P = 0.052). In 31 isolates no major change in the low MIC values before and after SDP was observed. PFGE showed clonal diversity in about half of the cases. Three isolates showed low-level resistance and three isolates high-level resistance to ciprofloxacin both before and after SDP. PFGE showed clonal identity in all cases. All patients had previously been treated with fluoroquinolones (FQ). In two isolates emergence of high-level resistance to ciprofloxacin after SDP occurred. PFGE showed clonal diversity in both cases. We conclude that after SDP with 500 mg ciprofloxacin there is a shift to gram-positive bacteria in the faeces and an increase in the rate of FQ resistance. Since selection of highly resistant E. coli is possible, a careful risk-benefit evaluation of prophylaxis with FQ is indicated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926443     DOI: 10.1016/s0924-8579(00)00182-5

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  [Infection and sepsis prevention in prostate biopsy].

Authors:  F M E Wagenlehner; A Pilatz; P Waliszewski; T Dansranjavin; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

Review 2.  Antibiotic prophylaxis in craniotomy: a review.

Authors:  Weiming Liu; Ming Ni; Yuewei Zhang; Rob J M Groen
Journal:  Neurosurg Rev       Date:  2014-02-13       Impact factor: 3.042

3.  Antibiotic prophylaxis in TURP: a prospective analysis concerning antibiotic stewardship and a potential reduction of antibiotic use in TURP.

Authors:  E Baten; F Van Der Aa; C Orye; R Cartuyvels; I Arijs; K van Renterghem
Journal:  World J Urol       Date:  2019-02-09       Impact factor: 4.226

Review 4.  Reducing infection rates after prostate biopsy.

Authors:  Florian M E Wagenlehner; Adrian Pilatz; Przemyslaw Waliszewski; Wolfgang Weidner; Truls E Bjerklund Johansen
Journal:  Nat Rev Urol       Date:  2014-01-14       Impact factor: 14.432

Review 5.  Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.

Authors:  Rachel M Greenblatt; Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-21       Impact factor: 3.254

6.  Rectal swab testing before prostate biopsy: experience in a VA Medical Center urology practice.

Authors:  I Cook; J B Angel; P L Vera; J Demos; D Preston
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-08-11       Impact factor: 5.554

7.  Quinolone prophylaxis in transrectal ultrasound guided prostate biopsy: an eight-year single center experience.

Authors:  Bing-Juin Chiang; Yeong Shiau Pu; Shiu-Dong Chung; Shih-Ping Liu; Hong-Jeng Yu; Shuo-Meng Wang; Hong-Chiang Chang; I-Ni Chiang; Chao-Yuan Huang
Journal:  ScientificWorldJournal       Date:  2013-12-23

8.  The molecular mechanisms of fluoroquinolone resistance found in rectal swab isolates of Enterobacterales from men undergoing a transrectal prostate biopsy: the rationale for targeted prophylaxis.

Authors:  Katarzyna Piekarska; Katarzyna Zacharczuk; Tomasz Wołkowicz; Mateusz Mokrzyś; Natalia Wolaniuk; Magdalena Nowakowska; Stanisław Szempliński; Jakub Dobruch; Rafał Gierczyński
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-12-07       Impact factor: 3.944

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.